ALX Oncology Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 2 with minor changes only.

1. Minor

   ASPEN-09-03 · Evorpacept in Combination With Trastuzumab and…ASPEN-09-03 · Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

   Trial sites expanded: 54 → 60 locations

   ALX Oncology Inc.·Phase 2· NCT07007559· Registry history of NCT07007559 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

2. Minor

   ALX2004 With Advanced or Metastatic Selected Solid Tumors

   Trial sites expanded: 8 → 12 locations

   ALX Oncology Inc.·Phase 1· NCT07085091· Registry history of NCT07085091 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.